CervoMed (CRVO) Other Non-Current Assets (2010 - 2024)
CervoMed (CRVO) posted Other Non-Current Assets of $73937.0 for Q3 2024, up 31.48% sequentially from $56234.0 in Q2 2024, and down 61.97% YoY from $194443.0 in Q4 2023.
CervoMed (CRVO) Other Non-Current Assets (2010 - 2024) Analysis & Trends
CervoMed has reported Other Non-Current Assets for 11 years, with the latest figure at $73937.0 in Q3 2024.
- Quarterly Other Non-Current Assets fell 61.97% year-over-year to $73937.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $73937.0 (down 61.97% YoY) and the FY2023 annual result came in at $7770.0, changed N/A from the prior year.
- Other Non-Current Assets advanced to $73937.0 in Q3 2024 per CRVO's latest filing, from $56234.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $252561.0 in Q1 2020 and troughed at $7770.0 in Q4 2023.
- A 4-year average of $92243.3 and a median of $31926.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2020 and 2021: Other Non-Current Assets slumped 95.11% in 2020, then declined 1.22% in 2021.
- Over 4 years, Other Non-Current Assets stood at $15771.0 in 2020, then decreased by 1.22% to $15578.0 in 2021, then slumped by 50.12% to $7770.0 in 2023, then jumped by 851.57% to $73937.0 in 2024.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $73937.0, $56234.0, and $31926.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 320,581.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 73,937.00 |
| Jun 30, 2024 | 56,234.00 |
| Mar 31, 2024 | 31,926.00 |
| Dec 31, 2023 | 7,770.00 |
| Sep 30, 2023 | 194,443.00 |
| Dec 31, 2021 | 15,578.00 |
| Sep 30, 2021 | 15,579.00 |
| Jun 30, 2021 | 15,578.00 |
| Mar 31, 2021 | 15,580.00 |
| Dec 31, 2020 | 15,771.00 |
| Sep 30, 2020 | 252,057.00 |
| Jun 30, 2020 | 252,149.00 |
| Mar 31, 2020 | 252,561.00 |
| Dec 31, 2019 | 322,301.00 |
| Sep 30, 2019 | 290,674.00 |
| Jun 30, 2019 | 291,176.00 |
| Mar 31, 2019 | 319,724.00 |
| Dec 31, 2018 | 298,480.00 |
| Sep 30, 2018 | 263,480.00 |
| Jun 30, 2018 | 262,214.00 |